AAAAAA
Results: 1-25/91
Authors:
BARTH S
HUHN M
WELS W
DIEHL V
ENGERT A
Citation: S. Barth et al., CONSTRUCTION AND IN-VITRO EVALUATION OF RFT5(SCFV)-ETA', A NEW RECOMBINANT SINGLE-CHAIN IMMUNOTOXIN WITH SPECIFIC CYTOTOXICITY TOWARD CD25(-DERIVED CELL-LINES() HODGKIN), INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 1(1), 1998, pp. 249-256
Authors:
SCHNELL R
VITETTA E
SCHINDLER J
BARTH S
WINKLER U
BORCHMANN P
HANSMANN ML
DIEHL V
GHETIE V
ENGERT A
Citation: R. Schnell et al., CLINICAL-TRIALS WITH AN ANTI-CD25 RICIN A-CHAIN EXPERIMENTAL AND IMMUNOTOXIN (RFT5-SMPT-DGA) IN HODGKINS-LYMPHOMA, Leukemia & lymphoma, 30(5-6), 1998, pp. 525
Authors:
JENSEN M
WINKLER U
MANZKE O
DIEHL V
ENGERT A
Citation: M. Jensen et al., RAPID TUMOR LYSIS IN A PATIENT WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA AND LYMPHOCYTOSIS TREATED WITH AN ANTI-CD20 MONOCLONAL-ANTIBODY (IDEC-C2B8, RITUXIMAB), Annals of hematology, 77(1-2), 1998, pp. 89-91
Authors:
JOSTING A
KATAY I
RUEFFER U
WINTER S
TESCH H
ENGERT A
DIEHL V
WICKRAMANAYAKE PD
Citation: A. Josting et al., FAVORABLE OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY HODGKINS-DISEASE TREATED WITH HIGH-DOSE CHEMOTHERAPY AND STEM-CELL RESCUE AT THE TIME OF MAXIMAL RESPONSE TO CONVENTIONAL SALVAGE THERAPY (DEXA-BEAM), Annals of oncology, 9(3), 1998, pp. 289-295
Authors:
LUNDIN J
OSTERBORG A
BRITTINGER G
CROWTHER D
DOMBRET H
ENGERT A
EPENETOS A
GISSELBRECHT C
HUHN D
JAEGER U
THOMAS J
MARCUS R
NISSEN N
POYNTON C
RANKIN E
STAHEL R
UPPENKAMP M
WILLEMZE R
MELLSTEDT H
Citation: J. Lundin et al., CAMPATH-1H MONOCLONAL-ANTIBODY IN THERAPY FOR PREVIOUSLY TREATED LOW-GRADE NON-HODGKINS-LYMPHOMAS - A PHASE-II MULTICENTER STUDY, Journal of clinical oncology, 16(10), 1998, pp. 3257-3263
Authors:
TESCH H
BOHLEN H
WOLF J
ENGERT A
Citation: H. Tesch et al., PATHOGENESIS AND TREATMENT OF HODGKINS-DI SEASE, Medizinische Klinik, 93(2), 1998, pp. 82-90
Authors:
HUBEL K
ENGERT A
SCHMITZ S
RE D
WASSERMANN K
KO Y
SCHWANDT C
VETTER H
DIEHL V
TESCH H
Citation: K. Hubel et al., PACLITAXEL, CARBOPLATIN, AND G-CSF IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE I II STUDY/, Onkologie, 21(4), 1998, pp. 310-314
Authors:
HUBEL K
SCHMITZ S
DIEHL V
ENGERT A
Citation: K. Hubel et al., TENTATIVE DIAGNOSIS OF LUNG-CANCER IN A PATIENT WITH LIPOID PNEUMONIA, Onkologie, 21(3), 1998, pp. 245-247
Authors:
MANSMANN G
ENGERT A
HUBEL K
Citation: G. Mansmann et al., APPLICATION OF G-CSF IN THE NONNEUTROPENIC HOST, Onkologie, 21(2), 1998, pp. 124-127
Authors:
REISER M
BORCHMANN P
DIEHL V
ENGERT A
Citation: M. Reiser et al., IFOSFAMIDE IN THE TREATMENT OF RELAPSED LYMPHOMA, Onkologie, 21, 1998, pp. 26-29
Authors:
WALSHE R
ENGERT A
DIEHL V
Citation: R. Walshe et al., CURRENT DEVELOPMENTS IN HEMATOLOGY AND ON COLOGICAL MEDICINE, Der Internist, 39(4), 1998, pp. 346-354
Authors:
COIFFIER B
KETTERER N
HAIOUN C
ENGERT A
TILLY H
MA D
JOHNSON P
LISTER A
FEURINGBUSKE M
RADFORD JA
REYES F
DIEHL V
Citation: B. Coiffier et al., A MULTICENTER, RANDOMIZED PHASE-II STUDY OF RITUXIMAB (MABTHERA) AT 2DOSAGES IN PATIENTS WITH RELAPSED OR REFRACTORY INTERMEDIATE GRADE LYMPHOMA OR IN ELDERLY PATIENTS IN FIRST-LINE THERAPY, British Journal of Haematology, 102(1), 1998, pp. 238-238
Authors:
COIFFIER B
HAIOUN C
KETTERER N
ENGERT A
TILLY H
MA D
JOHNSON P
LISTER A
FEURINGBUSKE M
RADFORD JA
CAPDEVILLE R
DIEHL V
REYES F
Citation: B. Coiffier et al., RITUXIMAB (ANTI-CD20 MONOCLONAL-ANTIBODY) FOR THE TREATMENT OF PATIENTS WITH RELAPSING OR REFRACTORY AGGRESSIVE LYMPHOMA - A MULTICENTER PHASE-II STUDY, Blood, 92(6), 1998, pp. 1927-1932
Authors:
SCHNELL R
BARTH S
DIEHL V
ENGERT A
Citation: R. Schnell et al., NON-HODGKINS-LYMPHOMA - A REVIEW OF IMMUNOTHERAPEUTIC APPROACHES TO TREATMENT, Biodrugs, 8(3), 1997, pp. 216-234
Authors:
ENGERT A
SCHNELL R
KUPPER F
REISER M
ENGELHARD M
WILHELM M
LATHAN B
BALTESENGLER S
WINTERHALTER B
SCHEULEN ME
DEDERICHS B
TESCH H
WORMANN B
DIEHL V
Citation: A. Engert et al., A PHASE-II STUDY WITH IDARUBICIN, IFOSFAMIDE AND VP-16 (IIVP-16) IN PATIENTS WITH REFRACTORY OR RELAPSED AGGRESSIVE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA, Leukemia & lymphoma, 24(5-6), 1997, pp. 513-522
Authors:
BARTH S
MATTHEY B
SCHON G
DIEHL V
ENGERT A
Citation: S. Barth et al., DEVELOPMENT OF A NEW RECOMBINANT ANTI-CD30 IMMUNOTOXIN (CD30L-ETA) FOR THE TREATMENT OF HODGKINS LYMPHOMA, European journal of cancer, 33, 1997, pp. 39-39
Authors:
MATTHEY B
ENGERT A
DIEHL V
BARTH S
Citation: B. Matthey et al., PBM1.1, A NEW PET-BASED VECTOR FOR HIGH-EFFICIENCY EXPRESSION OF ETA FUSION TOXINS, European journal of cancer, 33, 1997, pp. 129-129
Authors:
WINKLER U
BARTH S
SCHNELL R
DIEHL V
ENGERT A
Citation: U. Winkler et al., THE EMERGING ROLE OF IMMUNOTOXINS IN LEUKEMIA AND LYMPHOMA, Annals of oncology, 8, 1997, pp. 139-146
Authors:
HUBEL K
TESCH H
KROGER B
SCHNELL R
BORCHMANN P
DIEHL V
ENGERT A
Citation: K. Hubel et al., A PHASE I II STUDY OF IDARUBICIN, DEXAMETHASONE AND INTERFERON-ALPHA (I-DEXA) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE-MYELOMA/, Leukemia, 11, 1997, pp. 47-51
Authors:
WINKLER U
RIEDER H
MARZ W
VOLIOTIS D
FRANZEN C
SCHMITZ S
REHDER H
DIEHL V
ENGERT A
Citation: U. Winkler et al., ESTABLISHMENT AND CHARACTERIZATION OF A NOVEL CELL-LINE FROM A PATIENT WITH AN ACUTE MYELOID-LEUKEMIA, FAB M6, WITH COMPLEX CHROMOSOMAL-ABERRATIONS, Experimental hematology, 25(8), 1997, pp. 446-446
Authors:
ENGERT A
SCHNELL R
BARTH S
DIEHL V
Citation: A. Engert et al., IMMUNOTHERAPEUTIC STRATEGIES IN LYMPHOMAS, Der Internist, 38(2), 1997, pp. 150-156
Authors:
BARTH S
WINKLER U
DIEHL V
ENGERT A
Citation: S. Barth et al., IMMUNOTOXINS - ACTIVITY AND USE IN MALIGN ANT DISEASES, Der Internist, 38(11), 1997, pp. 1063-1069
Authors:
BOHLEN H
MANZKE O
TITZER S
LORENZEN J
KUBE D
ENGERT A
ABKEN H
WOLF J
DIEHL V
TESCH H
Citation: H. Bohlen et al., PREVENTION OF EPSTEIN-BARR-VIRUS-INDUCED HUMAN B-CELL LYMPHOMA IN SEVERE COMBINED IMMUNODEFICIENT MICE TREATED WITH CD3XCD19 BISPECIFIC ANTIBODIES, CD28 MONOSPECIFIC ANTIBODIES, AND AUTOLOGOUS T-CELLS, Cancer research, 57(9), 1997, pp. 1704-1709
Authors:
WINKLER U
RIEDER H
MARZ W
VOLIOTIS D
FRANZEN C
SCHMITZ S
REHDER H
DIEHL V
ENGERT A
Citation: U. Winkler et al., ESTABLISHMENT OF A HUMAN MYELOID CELL-LINE FROM THE FIRST PATIENT WITH ROTHMUND-THOMSON-SYNDROME AND ACUTE MYELOID-LEUKEMIA, Blood, 90(10), 1997, pp. 3800-3800
Authors:
MANSMANN G
HUBEL K
SCHAFER H
OBERHAUSER F
WASSMER G
DIEHL V
ENGERT A
Citation: G. Mansmann et al., INCREASE OF ANTIINFLAMMATORY CYTOKINES AND REDUCTION OF POSTOPERATIVEINFECTIONS BY PERIOPERATIVE TREATMENT WITH GRANULOCYTE-COLONY-STIMULATING FACTOR OF PATIENTS WITH ESOPHAGEAL CANCER, Blood, 90(10), 1997, pp. 764-764